34 related articles for article (PubMed ID: 11343868)
1. Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.
de Bartolomeis A; Ciccarelli M; De Simone G; Mazza B; Barone A; Vellucci L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983018
[TBL] [Abstract][Full Text] [Related]
2. Methylation pattern and mRNA expression of synapse-relevant genes in the MAM model of schizophrenia in the time-course of adolescence.
Khan AQ; Thielen L; Le Pen G; Krebs MO; Kebir O; Groh A; Deest M; Bleich S; Frieling H; Jahn K
Schizophrenia (Heidelb); 2022 Dec; 8(1):110. PubMed ID: 36481661
[TBL] [Abstract][Full Text] [Related]
3. Serum Level of Growth-Associated Protein 43 Is Associated with First-Episode Schizophrenia Patients without Antipsychotic Drugs Treatment.
Xiao L; Tang X; Hu X; Feng X; Gong R; Wang F; Zhang X
Comput Intell Neurosci; 2022; 2022():4719271. PubMed ID: 35615548
[TBL] [Abstract][Full Text] [Related]
4. Effect of Haloperidol and Risperidone on Serum Melatonin and GAP-43 in Patients with Schizophrenia: A Prospective Cohort Study.
Maiti R; Mishra BR; Jena M; Mishra A; Nath S
Clin Psychopharmacol Neurosci; 2021 Feb; 19(1):125-134. PubMed ID: 33508796
[TBL] [Abstract][Full Text] [Related]
5. Genetic association of the human GAP43 gene with schizophrenia in a Northeast Chinese Han population.
Luan Z; Ming W; Huo X; Yu J; Wang B; Sun Y
Indian J Psychiatry; 2020; 62(4):413-417. PubMed ID: 33165371
[TBL] [Abstract][Full Text] [Related]
6. Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures.
Osimo EF; Beck K; Reis Marques T; Howes OD
Mol Psychiatry; 2019 Apr; 24(4):549-561. PubMed ID: 29511299
[TBL] [Abstract][Full Text] [Related]
7. Molecular evidence for decreased synaptic efficacy in the postmortem olfactory bulb of individuals with schizophrenia.
Egbujo CN; Sinclair D; Borgmann-Winter KE; Arnold SE; Turetsky BI; Hahn CG
Schizophr Res; 2015 Oct; 168(1-2):554-62. PubMed ID: 26260078
[TBL] [Abstract][Full Text] [Related]
8. Rethinking schizophrenia in the context of normal neurodevelopment.
Catts VS; Fung SJ; Long LE; Joshi D; Vercammen A; Allen KM; Fillman SG; Rothmond DA; Sinclair D; Tiwari Y; Tsai SY; Weickert TW; Shannon Weickert C
Front Cell Neurosci; 2013; 7():60. PubMed ID: 23720610
[TBL] [Abstract][Full Text] [Related]
9. The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus.
Hradetzky E; Sanderson TM; Tsang TM; Sherwood JL; Fitzjohn SM; Lakics V; Malik N; Schoeffmann S; O'Neill MJ; Cheng TM; Harris LW; Rahmoune H; Guest PC; Sher E; Collingridge GL; Holmes E; Tricklebank MD; Bahn S
Neuropsychopharmacology; 2012 Jan; 37(2):364-77. PubMed ID: 21956444
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide association study of schizophrenia in Japanese population.
Yamada K; Iwayama Y; Hattori E; Iwamoto K; Toyota T; Ohnishi T; Ohba H; Maekawa M; Kato T; Yoshikawa T
PLoS One; 2011; 6(6):e20468. PubMed ID: 21674006
[TBL] [Abstract][Full Text] [Related]
11. Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients.
Fung SJ; Sivagnanasundaram S; Weickert CS
Biol Psychiatry; 2011 Jan; 69(1):71-9. PubMed ID: 21145444
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine.
Chana G; Lucero G; Salaria S; Lozach J; Du P; Woelk C; Everall I
Schizophr Res; 2009 Sep; 113(2-3):273-6. PubMed ID: 19502011
[TBL] [Abstract][Full Text] [Related]
13. Early parental deprivation in the marmoset monkey produces long-term changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder.
Law AJ; Pei Q; Walker M; Gordon-Andrews H; Weickert CS; Feldon J; Pryce CR; Harrison PJ
Neuropsychopharmacology; 2009 May; 34(6):1381-94. PubMed ID: 18615010
[TBL] [Abstract][Full Text] [Related]
14. Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.
Brown JS
Schizophr Bull; 2009 Jan; 35(1):256-78. PubMed ID: 18245062
[TBL] [Abstract][Full Text] [Related]
15. Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients.
Weickert CS; Rothmond DA; Hyde TM; Kleinman JE; Straub RE
Schizophr Res; 2008 Jan; 98(1-3):105-10. PubMed ID: 17961984
[TBL] [Abstract][Full Text] [Related]
16. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.
Harrison PJ
Psychopharmacology (Berl); 2004 Jun; 174(1):151-62. PubMed ID: 15205886
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia.
Vawter MP; Shannon Weickert C; Ferran E; Matsumoto M; Overman K; Hyde TM; Weinberger DR; Bunney WE; Kleinman JE
Neurochem Res; 2004 Jun; 29(6):1245-55. PubMed ID: 15176481
[TBL] [Abstract][Full Text] [Related]
18. Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue.
Dean B
Postgrad Med J; 2002 Mar; 78(917):142-8. PubMed ID: 11884695
[TBL] [Abstract][Full Text] [Related]
19. Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia.
Webster MJ; Shannon Weickert C; Herman MM; Hyde TM; Kleinman JE
Schizophr Res; 2001 Apr; 49(1-2):89-98. PubMed ID: 11343868
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
